Next Generation Drug Conjugates Market

The next generation drug conjugates market is projected to reach USD 42.55 billion by 2035 from USD 15.75 billion in 2026, at a CAGR of 11.7%. The growth of the next generation drug conjugates market is driven by the rising burden of cancer and other chronic diseases, along with continued advancements in targeting ligands, linker technologies, and novel payload platforms. Additionally, increasing investment in research and development, strategic collaborations, and expanding clinical pipelines for antibody-drug conjugates, radioligand therapies, and oligonucleotide conjugates are further expected to support market growth.

The global next generation drug conjugates market is consolidated with top players such as AstraZeneca (UK), Daiichi Sankyo, Inc. (Japan), Alnylam Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), Gilead Biosciences, Inc. (US), ADC Therapeutics (US) and Ionis Pharmaceuticals, Inc. (US), among others. The market players have adopted various strategies, such as new product approvals and launches, acquisitions, agreements, collaborations, partnerships, and geographical expansions, to strengthen their position in the global next generation drug conjugates market.

To know about the assumptions considered for the study download the pdf brochure

AstraZeneca (US)

AstraZeneca is a global biopharmaceutical company with a strong oncology focus and a leading position in the next generation drug conjugates market. The company has built significant momentum in this space through its antibody-drug conjugate portfolio, particularly ENHERTU (trastuzumab deruxtecan), which is jointly developed and commercialized with Daiichi Sankyo, and DATROWAY / datopotamab deruxtecan, another key DXd-based ADC within its oncology portfolio. Its strategy is supported by a strong commercial footprint, broad clinical development activity, and continued focus on targeted, precision-based cancer therapies.

Novartis AG (Switzerland)

Novartis is a global innovative medicines company with a leading position in the next generation drug conjugates market, particularly through its strong radioligand therapy platform in oncology. The company has established a major commercial presence in this space with PLUVICTO (lutetium Lu 177 vipivotide tetraxetan) and LUTATHERA (lutetium Lu 177 dotatate), both of which represent targeted radioligand therapies that combine a targeting ligand with a radioisotope payload.

Alnylam Pharmaceuticals, Inc. (US)

Alnylam Pharmaceuticals is a leading RNAi therapeutics company with a strong position in the next generation drug conjugates market through its GalNAc-siRNA conjugate platform. The company has built a differentiated presence in this space with commercialized products such as AMVUTTRA (vutrisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran), which use Alnylam’s ESC/ESC+ GalNAc-conjugate technology for targeted delivery to hepatocytes. Alnylam continues to invest heavily in expanding this platform across rare disease and broader cardiometabolic indications, supported by a robust pipeline and continued innovation in RNAi delivery.

Gilead Sciences, Inc. (US)

Gilead Sciences is a global biopharmaceutical company with a growing presence in the next generation drug conjugates market through its oncology franchise. The company’s key marketed drug conjugate is TRODELVY (sacituzumab govitecan), a Trop-2-directed antibody-drug conjugate with an SN-38 topoisomerase I inhibitor payload, positioning Gilead within the newer wave of ADCs built on targeted delivery and differentiated payload technology.

Related Reports:

Next Generation Drug Conjugates Market by Product (Enhertu, Amvuttra), Type (Antibody-Small Molecule), Target Ligand (Antibody, Peptide), Payload Type (Oligonucleotide, Radionuclide), Indication (Breast Cancer, Prostate Cancer) - Global Forecast to 2035

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]